Introgen Therapeutics announced that a preliminary analysis of a late-stage trial of Advexin confirmed their mid-stage efficacy data for patients with recurrent head and neck cancer. And researchers added that a biomarker for the gene target is predictive for identifying patients likely to respond to the therapy. Austin-based Introgen says it will file for approval in U.S. and Europe this quarter.
"Advexin provides therapeutic benefit by restoring p53 tumor suppressor function which is blocked in the majority of head and neck cancers," said Robert E. Sobol, senior vice president, medical and scientific affairs.
- check out the release
- read the report from BioWorld
Related Articles:
Introgen reports biomarker link to new therapy. Introgen report
Introgen touts cancer data. Introgen report